COVID-19 in patients with demyelinating diseases of the central nervous system

Takeaway

  • Case fatality and hospitalization rates from COVID-19 in people with central nervous system (CNS) demyelinating diseases in the northeastern US were similar to previously reported multiple sclerosis (MS) cohorts and the general population. Hospitalization was associated with increased disability, age, and comorbidities.

Why this matters

  • COVID-19 is the third worst pandemic in modern history and has negatively impacted health outcomes around the world. The pandemic has been particularly concerning for those with pre-existing medical conditions, such as those with CNS demyelinating diseases.

  • An investigation of the risk factors and severity of COVID-19 in people with MS and other CNS demyelinating diseases is warranted to better inform patient care decisions during the COVID-19 pandemic.